Randomized phase III trial of fludarabine plus cyclophosphamide with or without oblimersen sodium (Bcl-2 antisense) in patients with relapsed or refractory chronic lymphocytic leukemia

Journal of Clinical Oncology

Volumn 25, Issue 9, 2007, Pages 1114-1120

  O'Brien, Susan ^a   Moore, Joseph O ^a   Boyd, Thomas E ^a   Larratt, Loree M ^a   Skotnicki, Aleksander ^a   Koziner, Benjamin ^a   Chanan Khan, Asher A ^a   Seymour, John F ^a   Bociek, R Gregory ^a   Pavletic, Steve ^a   Rai, Kanti R ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ALLOPURINOL; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; ERYTHROPOIETIN; FLUDARABINE; OBLIMERSEN; PROTEIN BCL 2; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; ALKYLATING AGENT; ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; DRUG DERIVATIVE; NUCLEOTIDE; VIDARABINE;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER RELAPSE; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; CYTOKINE RELEASE; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG RESPONSE; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; FEMALE; FEVER; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; OPPORTUNISTIC INFECTION; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RIGOR; THROMBOCYTOPENIA; TREATMENT OUTCOME; TUMOR LYSIS SYNDROME; VOMITING; DRUG ADMINISTRATION; FOLLOW UP; GENETICS; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; PROPORTIONAL HAZARDS MODEL; PROTO ONCOGENE; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; TIME; TREATMENT FAILURE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; GENES, BCL-2; HUMANS; KAPLAN-MEIERS ESTIMATE; LEUKEMIA, LYMPHOCYTIC, CHRONIC; MALE; MIDDLE AGED; OLIGONUCLEOTIDES, ANTISENSE; PROPORTIONAL HAZARDS MODELS; RECURRENCE; THIONUCLEOTIDES; TIME FACTORS; TREATMENT FAILURE; TREATMENT OUTCOME; VIDARABINE;

EID: 34047217206     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2006.07.1191     Document Type: Article

References (38)

1. Keating MJ, O'Brien S, Albitar M, et al: Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol 23:4079-4088, 2005
2. Keating MJ, O'Brien S, Lerner S, et al: Long-term follow-up of patients with chronic lymphocytic leukemia (CLL) receiving fludarabine regimens as initial therapy. Blood 92:1165-1171, 1998
3. Wierda W, O'Brien S, Wen S, et al: Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia. J Clin Oncol 23:4070-4078, 2005
4. Kitada S, Reed JC, Lucas DM, et al: Critical molecular studies to strategically plan therapy in chronic lymphocytic leukemia (CLL): Correlating cellular proteins with defined prognostic patient subsets and their response to treatment. Blood 104: 274a, 2004 (abstr 956)
5. Damle RN, Wasil T, Fais F, et al: Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 94:1840-1847, 1999
6. Ibrahim S, Keating M, Do K-A, et al: CD38 expression as an important prognostic factor in B-cell chronic lymphocytic leukemia. Blood 98:181-186, 2001
7. Hus I, Podhorecka M, Bojarska-Junak A, et al: The clinical significance of ZAP-70 and CD38 expression in B-cell chronic lymphocytic leukaemia. Ann Oncol 17:683-690, 2006
8. Rassenti LZ, Huynh L, Toy TL, et al: ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia. N Engl J Med 351:893-901, 2004
9. Crespo M, Bosch F, Villamor N, et al: ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. N Engl J Med 348:1764-1775, 2003
10. Faderl S, Keating MJ, Do K-A, et al: Expression profile of 11 proteins and their prognostic significance in patients with chronic lymphocytic leukemia. Leukemia (CLL) 16:1045-1052, 2002
11. Hanada M, Delia D, Aiello A, et al: bcl-2 gene hypomethylation and high-level expression in B-cell chronic lymphocytic leukemia. Blood 82:1820-1828, 1993
12. Robertson LE, Plunkett W, McConnell K, et al: Bcl-2 expression in chronic lymphocytic leukemia and its correlation with the induction of apoptosis and clinical outcome. Leukemia 10:456-459, 1996
13. Schena M, Larsson L-G, Gottardi D, et al: Growth- and differentiation-associated expression of bcl-2 in B-chronic lymphocytic leukemia cells. Blood 79:2981-2989, 1992
14. Reed JC, Kitada S, Takayama S, et al: Regulation of chemoresistance by the bcl-2 oncoprotein in non-Hodgkin's lymphoma and lymphocytic leukemia cell lines. Ann Oncol 5:S61-S65, 1994 (suppl 1)
15. Klasa RJ, Gillum AM, Klem RE: Oblimersen Bcl-2 antisense: Facilitating apoptosis in anticancer treatment. Antisense Nucleic Acid Drug Dev 12:193-213, 2002
16. Cimmino A, Calin GA, Fabbri M, et al: MiR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci U S A 102:13944-13949, 2005
17. Calin GA, Croce CM. Genomics of chronic lymphocytic leukemia microRNAs as new players with clinical significance. Semin Oncol 33:167-173, 2006
18. Meijerink JP, Van Lieshout EM, Beverloo HB, et al: Novel murine B-cell lymphoma/leukemia model to study BCL2-driven oncogenesis. Int J Cancer 114:917-925, 2005
19. Curcio LD, Bouffard DY, Scanlon KJ: Oligonucleotides as modulators of cancer gene expression. Pharmacol Ther 74:317-332, 1997
20. Pepper C, Thomas A, Hoy T, et al: Antisense-mediated suppression of Bcl-2 highlights its pivotal role in failed apoptosis in B-cell chronic lymphocytic leukaemia. Br J Haematol 107:611-615, 1999
21. Pepper C, Hooper K, Thomas A, et al: Bcl-2 antisense oligonucleotides enhance the cytotoxicity of chlorambucil in B-cell chronic lymphocytic leukaemia cells. Leuk Lymphoma 42:491-498, 2001
22. Jahrsdorfer B, Jox R, Muhlenhoff L, et al: Modulation of malignant B cell activation and apoptosis by bcl-2 antisense ODN and immunostimulatory CpG ODN. J Leukoc Biol 72:83-92, 2002
23. Castro JE, Prada CE, Aguillon RA, et al: Thymidine-phosphorothioate oligonucleotides induce activation and apoptosis of CLL cells independently of CpG motifs or BCL-2 gene interference. Leukemia 20:680-688, 2006
24. Cotter FE, Corbo M, Raynaud F, et al: Bcl-2 antisense therapy in lymphoma: In vitro and in vivo mechanisms, efficacy, pharmacokinetic and toxicity studies. Ann Oncol 7:32, 1996 (suppl 3: abstr 100)
25. Cotter FE, Waters J, Cunningham D: Human Bcl-2 antisense therapy for lymphomas. Biochim Biophys Acta 1489:97-106, 1999
26. Waters JS, Clarke PA, Cunningham D, et al: BCL-2 antisense oligodeoxynucleotide (ODN) (G3139) therapy exerts its anti-tumor action through a sequence-specific antisense effect, and not a cell-mediated immune response. Proc Am Soc Clin Oncol 19:14a, 2000 (abstr 48)
27. Auer RL, Corbo M, Fegan CD, et al: Bcl-2 antisense (Genasense) induces apoptosis and potentiates activity of both cytotoxic chemotherapy and rituximab in primary CLL cells. Blood 98:808a, 2001 (abstr 3358)
28. Castro JE, Kitada S, Mota M, et al: Phosphorothioate oligodeoxynucleotides can induce apoptosis of chronic lymphocytic leukemia B cells via a mechanism that does not depend upon specific interference of BCL-2 gene expression. Blood 100: 379a, 2002 (abstr 1470)
29. Cotter FE, Auer R, Corbo M, et al: Oblimersen sodium (G3139) sensitizes malignant B-cells to alemtuzumab (Ab) induced apoptosis. Proc Am Soc Clin Oncol 22:227, 2003 (abstr 910)
30. Dai G, Chan KK, Liu S, et al: Cellular uptake and intracellular levels of the Bcl-2 antisense G3139 in cultured cells and treated patients with acute myeloid leukemia. Clin Cancer Res 11:2998-3008, 2005
31. Chiu SJ, Liu S, Perrotti D, et al: Efficient delivery of a Bcl-2-specific antisense oligodeoxyribonucleotide (G3139) via transferrin receptor-targeted liposomes. J Control Release 112:199-207, 2006
32. O'Brien SM, Cunningham CC, Golenkov AK, et al: Phase I to II multicenter study of oblimersen sodium, a Bcl-2 antisense oligonucleotide, in patients with advanced chronic lymphocytic leukemia. J Clin Oncol 23:7697-7702, 2005
33. Rai KR, O'Brien S, Cunningham C, et al: Genasense (Bcl-2 antisense) monotherapy in patients with relapsed or refractory chronic lymphocytic leukemia: Phase 1 and 2 results. Blood 100: 384a, 2002 (abstr 1490)
34. Cheson BD, Bennett JM, Grever M, et al: National Cancer Institute-sponsored working group guidelines for chronic lymphocytic leukemia: Revised guidelines for diagnosis and treatment. Blood 87:4990-4997, 1996
35. O'Brien SM, Kantarjian HM, Cortes J, et al: Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia. J Clin Oncol 19:1414-1420, 2001
36. Byrd JC, Peterson BL, Morrison VA, et al: Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: Results from Cancer and Leukemia Group B 9712 (CALGB 9712). Blood 101:6-14, 2003
37. Wendtner C-M, Ritgen M, Schweighofer CD, et al: Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission: Experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG). Leukemia 18: 1093-1101, 2004
38. Eichhorst BF, Busch R, Hopfinger, et al: Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia. Blood 107:885-891, 2006